Invivyd, Inc. financial data

Symbol
IVVD on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
1601 Trapelo Road, Suite 178, Waltham, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Adagio Therapeutics, Inc. (to 9/12/2022)
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 695 % -31%
Debt-to-equity 17.1 % +49.8%
Return On Equity -93.6 % -96.1%
Return On Assets -79.9 % -86.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 119 M shares +9.19%
Common Stock, Shares, Outstanding 119 M shares +9.06%
Entity Public Float 67.1 M USD -70.6%
Common Stock, Value, Issued 12 K USD +9.09%
Weighted Average Number of Shares Outstanding, Basic 116 M shares +6.28%
Weighted Average Number of Shares Outstanding, Diluted 116 M shares +6.28%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 163 M USD +42.2%
Operating Income (Loss) -220 M USD -17.9%
Nonoperating Income (Expense) 13 M USD +24.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -207 M USD -17.5%
Earnings Per Share, Basic -1.87 USD/shares -15.4%
Earnings Per Share, Diluted -1.87 USD/shares -15.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 189 M USD +49.7%
Inventory, Net 109 K USD
Assets, Current 210 M USD -39.1%
Property, Plant and Equipment, Net 1.9 M USD -15.6%
Operating Lease, Right-of-Use Asset 1.83 M USD -46.2%
Other Assets, Noncurrent 1.86 M USD +538%
Assets 215 M USD -38.5%
Accounts Payable, Current 1.17 M USD -80.2%
Accrued Liabilities, Current 34 M USD +134%
Liabilities, Current 36.3 M USD +64.8%
Operating Lease, Liability, Noncurrent 625 K USD -64.4%
Other Liabilities, Noncurrent 0 USD
Liabilities 37 M USD +55.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -12 K USD +89.6%
Retained Earnings (Accumulated Deficit) -776 M USD -36.4%
Stockholders' Equity Attributable to Parent 178 M USD -45.4%
Liabilities and Equity 215 M USD -38.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -50.2 M USD -21.9%
Net Cash Provided by (Used in) Financing Activities 39.1 M USD +7114%
Net Cash Provided by (Used in) Investing Activities -140 K USD -100%
Common Stock, Shares Authorized 1 B shares 0%
Common Stock, Shares, Issued 119 M shares +9.06%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.3 M USD -133%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 189 M USD +49.7%
Deferred Tax Assets, Valuation Allowance 200 M USD +52.6%
Deferred Tax Assets, Gross 201 M USD +52.1%
Operating Lease, Liability 435 K USD +0.69%
Depreciation 122 K USD +1.67%
Payments to Acquire Property, Plant, and Equipment 140 K USD -77.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -207 M USD -17.4%
Lessee, Operating Lease, Liability, to be Paid 1.69 M USD
Operating Lease, Liability, Current 1.13 M USD -28.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 421 K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 411 K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 430 K USD
Deferred Tax Assets, Operating Loss Carryforwards 76.4 M USD +24%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 328 K USD
Operating Lease, Payments 432 K USD +57.1%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 699 K USD -21.9%
Share-based Payment Arrangement, Expense 18.7 M USD -25.5%
Operating Leases, Future Minimum Payments Due 108 M USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%